What Wegovy actually does to your body — and what it doesn't

The myth: Wegovy is just an appetite suppressant you take instead of dieting

This is the most common misreading, and it shapes how disappointed some people feel when results take time. Wegovy isn't a drug that overrides hunger like a switch. It works with biology that's already there. Your gut naturally releases a hormone called GLP-1 (glucagon-like peptide-1) after you eat. That hormone tells your brain you've had enough, tells your pancreas to release insulin, and slows the passage of food from the stomach into the small intestine. Semaglutide is a synthetic version of that hormone, engineered to last much longer in the body than your own GLP-1 does.

The practical result is that the signal your brain receives after a meal is stronger and more sustained. Food cravings don't vanish, but many people describe a shift in how loud those cravings feel. That's not the same as willpower suddenly improving. The biology is doing something different. A closer look at the mechanism explains how each part of that process unfolds week by week. What Wegovy cannot do is target specific fat deposits, accelerate your resting metabolic rate, or substitute for the lifestyle changes a prescriber will discuss with you.

Weight is a health condition with biological drivers, not a simple deficit equation, and framing Wegovy as a shortcut misses what the medicine actually is: a tool that lowers the biological pressure that makes sustained eating changes so difficult. If you want to understand what Wegovy does to your body in fuller detail, the NHS semaglutide medicines page also sets out the picture in plain terms alongside that. The NHS semaglutide medicines page sets out the full picture in plain terms.

What the body does differently on Wegovy, week by week

The first pen contains the 0.25mg starter dose. At this level, therapeutic weight loss is not the goal. The job of the early weeks is to let your digestive system adjust so that the side effects most people worry about, mainly nausea, loose stools and indigestion, are manageable from the start. Doses increase roughly every four weeks, guided by your prescriber, up to the 2.4mg maintenance dose. If you're wondering whether Wegovy at a higher dose can go further, the MHRA approved a dedicated 7.2mg pen in April 2026, the details of that approval are worth reading if you're comparing your options.

Once at maintenance dose, the effects on digestion become more consistent. Gastric emptying slows measurably. Appetite signals remain dampened. Blood-sugar spikes after meals are flatter, even in people without diabetes, because semaglutide also nudges the pancreas to release insulin in a glucose-dependent way. That means insulin production responds to what you've actually eaten, not just a fixed schedule.

Physically, many people notice they feel full on smaller portions, lose interest in food between meals and feel less driven by the reward cues that make snacking habitual. That shift is real neuroscience: GLP-1 receptors exist in the brain as well as the gut, and semaglutide reaches them. People sometimes also ask whether Ozempic and Wegovy are exactly the same, since both contain semaglutide but are licensed for different purposes and come in different doses. For a broader overview of how semaglutide acts on the body, this page on semaglutide's effects covers the evidence in more detail.

Side effects: what commonly happens and when to seek help

The most frequently reported effects are gastrointestinal: nausea, vomiting, constipation, diarrhoea, burping and abdominal discomfort. For most people these are mild to moderate and tend to settle within days to a couple of weeks of a dose increase, rather than persisting throughout treatment. Fatigue, headache and dizziness appear less often. Injection-site reactions (redness or mild soreness where the pen is used) are also reported.

If you're reading this because you or someone you care about is nervous about starting, that's understandable. Side effects can sound alarming on a list. The reality for most people is that they're an inconvenience during dose increases, not a reason to stop, and your prescriber's job includes helping you manage them.

There are symptoms that require prompt medical attention. Severe, persistent stomach pain that radiates through to the back, with or without vomiting, can indicate acute pancreatitis. The MHRA highlighted this as a known but infrequent serious effect in a Drug Safety Update issued in January 2026. Signs of an allergic reaction, gallbladder symptoms (sharp pain in the upper right abdomen), and any sudden changes in vision also warrant same-day medical contact. You can report suspected side effects, including reactions from any medicine, through the MHRA Yellow Card scheme. Wegovy carries a Black Triangle (▼) status, meaning the MHRA actively monitors new safety information as it emerges from real-world use.

Who is Wegovy licensed for, and what comes next

In the UK, Wegovy is licensed for adults with a BMI of 30 or above, or for those with a BMI of 27 to 29.9 who have at least one weight-related health condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Pregnancy, breastfeeding and trying to conceive are situations where Wegovy is not recommended. It isn't licensed for anyone under 18.

If you're thinking about whether this treatment might suit you, the honest starting point is a clinical consultation, not a price comparison. A prescriber looks at your full health picture: current medicines, medical history, and whether there are any reasons this particular treatment isn't the right fit. For context on how Wegovy compares with other options, the weight-loss treatment overview sets out what's available and how the choices differ. If you'd like to discuss your situation with our team, a little about how nume works might help you feel confident before you start. There's no pressure, just a free consultation, reviewed by a real prescriber the same day, with no commitment until you're ready. Check your eligibility when you're prepared to take that step.